Issue link: http://clhia.uberflip.com/i/406567
27 order to continue with drug they are currently taking or even potentially losing coverage they currently have. There is much scope for greater alignment of processes and collaboration across plans in Canada that would benefit physicians, pharmacists and Canadians. THEREFORE, THE CLHIA RECOMMENDS THAT: • PROVINCIAL GOVERNMENTS COMMIT AS A PRIORITY, TO WORK WITH PRIVATE PAYERS TO DEVELOP TRANSPARENT AND EFFICIENT OPERATIONAL PROCESSES TO FACILITATE THE SEAMLESS TRANSITION OF PATIENTS BETWEEN PUBLIC AND PRIVATE COVERAGE . c.2 Development of Common National Minimum Formulary Lack of harmonization on which drugs are covered in different public and private plans is a key frustration with the current system in Canada. Different drugs can be available to patients depending on their province and/or the plan design chosen by their employer. This may be particularly pronounced for new drugs. This complexity is problematic for prescribers and patients and ultimately undermines Canadians' confidence in the system. The industry believes that Canadians would benefit from the establishment of a common national minimum formulary. A national minimum formulary would ensure a baseline of coverage for all Canadians and would reduce some of the existing complexity in the system. This would offer consistency across jurisdictions and coverage, which would benefit both consumers and prescribers across Canada. Moreover, this could help reduce the costs associated with the complexity of the system. In order for such a minimum standard formulary to be meaningful for Canadians, it would need to be comprehensive enough to address coverage of drugs that treat chronic illness and rare diseases. Such an approach would still allow those provinces, plan sponsors or individuals, who want additional coverage to have it.